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Integrating Patient-Reported Measures into Routine Cancer Care: Cancer
Patients’ and Clinicians’ Perceptions of Acceptability and Value
Abstract
Introduction: Despite growing interest in integrating patient-reported outcome (PRO) measures of
symptoms and functional status into routine cancer care, little attention has been paid to patients’ and
clinicians’ perceptions of acceptability and value.
Methods: A two-phase qualitative study was conducted to develop a web-based PRO screening system with
21 items assessing symptoms (e.g., nausea) and functional status. Phase 1 involved cognitive interviews with
35 cancer outpatients (n=9 breast chemotherapy, radiation for prostate (n=8) or head and neck cancer
(n=10), and n=8 bone marrow transplant [BMT]). In Phase 2, we evaluated the acceptability and perceived
value of reviewing a PRO measure during real-time clinical encounters with 39 additional outpatients (n=10
breast, n=9 head and neck, n=10 prostate, n=10 BMT) and 12 clinicians (n=3 breast, n=2 head and neck, n=4
prostate, n=3 BMT). At least 20% of patients were ≥60 years, African American, or ≤ high school.
Results: Patients felt that their PRO summary of symptoms and functional status was helpful in discussing
health issues with clinicians (92%), wanted to review their results with clinicians during future visits (82%),
and would recommend it to other patients (87%). Clinicians found the PRO summary to be easy to interpret
(83%), most helpful for documenting the Review of Symptoms (92%), and would recommend it to future
patients (92%). Over 90% of clinicians reported that consultation time did not increase.
Conclusion: Both cancer patients and clinicians reported that discussing a PRO summary of symptoms and
functional status during an outpatient visit was useful, acceptable, and feasible.
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Introduction: Despite growing interest in integrating patient-reported outcome (PRO) measures of 
symptoms and functional status into routine cancer care, little attention has been paid to patients’ and 
clinicians’ perceptions of acceptability and value.
Methods: A two-phase qualitative study was conducted to develop a web-based PRO screening system 
with 21 items assessing symptoms (e.g., nausea) and functional status. Phase 1 involved cognitive 
interviews with 35 cancer outpatients (n=9 breast chemotherapy, radiation for prostate (n=8) or 
head and neck cancer (n=10), and n=8 bone marrow transplant [BMT]). In Phase 2, we evaluated the 
acceptability and perceived value of reviewing a PRO measure during real-time clinical encounters with 
39 additional outpatients (n=10 breast, n=9 head and neck, n=10 prostate, n=10 BMT) and 12 clinicians 
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Results: Patients felt that their PRO summary of symptoms and functional status was helpful in discussing 
health issues with clinicians (92%), wanted to review their results with clinicians during future visits (82%), 
and would recommend it to other patients (87%). Clinicians found the PRO summary to be easy to interpret 
(83%), most helpful for documenting the Review of Symptoms (92%), and would recommend it to future 
patients (92%). Over 90% of clinicians reported that consultation time did not increase.
Conclusion: Both cancer patients and clinicians reported that discussing a PRO summary of symptoms 
and functional status during an outpatient visit was useful, acceptable, and feasible.
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Introduction
The Affordable Care Act emphasizes personalized 
medicine and health information technology (HIT) 
to improve quality of care and manage health 
care costs.1-3 An important aspect of personalized 
medicine is to integrate real-time, patient-reported 
outcome (PRO) measures into routine clinical visits. 
Current practice standards in oncology involve 
a clinician assessing a patient through open-
ended questions, performing an exam, and then 
interpreting the patient’s responses about symptoms 
and functional impact. In many hospital systems 
and practices, standardized PRO measures are not 
administered or discussed with the patient during 
routine visits. However, the gold standard is to assess 
symptoms and functional status by patient report4 
because providers tend to underdetect symptom 
onset,5-8 severity,9 and frequency of symptoms.8
Despite interest in using PRO measures during 
outpatient visits, little attention has been paid to 
clinicians’ and patients’ perceptions of acceptability 
and value. Reviewing PRO measures during clinical 
care provides an opportunity for the patient to 
clarify and elaborate on treatment side effects and 
other symptoms that may need to be managed.10 
A systematic review of controlled trials showed 
that reviewing PRO measures with cancer patients 
increases discussion of symptoms such as pain and 
emotional distress.11 It may also increase providers’ 
detection and management of symptoms. For 
instance, oncology clinicians randomized to receive 
feedback from a PRO pain measure were more likely 
to make prescription changes for patients in the 
intervention group.12 This increase in communication 
and management of symptoms that occurs when PRO 
measures are reviewed may be why patients report 
having higher well-being13 and satisfaction with care.11
Less information is available about clinicians’ 
perceptions of value and acceptability. Three prior 
studies have examined oncologists’ perceptions of 
the advantages and disadvantages of discussing 
PRO measures with their patients during future 
clinical visits.14-16 The main advantages were 
the identifying and rectifying of problematic 
symptoms.14-16 Oncologists expressed concerns 
over potential patient burden, increasing 
consultation time, cost, inefficiency, staffing needs, 
and depersonalization of the physician-patient 
encounter.14-16 Clinicians in these studies were asked 
to imagine hypothetical scenarios, and thus no 
studies have been conducted during real-time 
testing to determine whether clinicians perceive it to 
be valuable and feasible to discuss a PRO measure 
during a routine visit.
Similarly, little research is available to inform best 
practices for integrating PRO questionnaires into 
routine care work flow and associated health 
information technology systems. Snyder et 
al. developed a user’s guide for implementing 
PROs in clinical practice.17 They noted a number 
of methodological and practical decisions that 
must be made, such as identifying the goals for 
collecting PROs; choosing questionnaires, timing 
of assessments, and mode of administration; 
developing processes for result reporting; and 
developing strategies for responding to issues 
identified by the PRO measures.17 This breadth of 
choices has led to heterogeneous implementation 
strategies across hospital systems. A recent 
systematic review concluded that there was 
substantial variation in the ways that 33 cancer 
hospital systems administered and integrated into 
clinical practice their web-based PRO measures.18 
Few of the electronic systems appeared to be 
developed with input from either clinicians or 
patients.18 It was also unclear if any of the systems 
had been developed with both clinician and patient 
stakeholder input.18 Thus, there is a need to develop 
and evaluate a web-based screening system to elicit 
patient-reported symptoms and functional status 
that considers what cancer patients and clinicians 
need during clinical encounters. A web-based 
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system was chosen because it permits immediate 
scoring and the creation of summaries highlighting a 
patient’s most problematic symptoms, and it can be 
immediately uploaded into an EHR.
Our primary objectives were the following: (1) solicit 
feedback from cancer clinicians and patients to 
develop a web-based screening system for securely 
administering and summarizing PRO measures for 
use during routine cancer care; and (2) pilot test 
the system during outpatient visits to evaluate 
cancer patients’ and clinicians’ perceptions of the 
acceptability and value of discussing PRO measures 
during clinical care.
Methods
We conducted a two-phase qualitative study to 
design the web-based Patient-Reported Symptom 
Monitoring (PRSM) system with stakeholder input 
from patients and clinicians. Our process was informed 
by the Consolidated Framework for Implementation 
Research (CFIR) in health services research.19 We used 
four CFIR domains to design a rigorous qualitative 
study: (1) patient characteristics; (2) patient needs; 
(3) clinician needs; and (4) evaluation of perceived 
acceptability, feasibility, and value.
In Phase 1, we evaluated a brief PRO screener for 
use across patients with different cancer types and 
a web-based system that collects patient responses 
in real time and summarizes responses to highlight 
the patient’s most problematic needs. In Phase 2, the 
PRO summaries were implemented into outpatient 
visits for usability testing. Both patients and 
clinicians reported on feasibility and perceived value. 
The two phases of development and evaluation are 
summarized in Figure 1.
Purposive Sampling of Cancer Patients
Three cancer clinics at a large academic medical 
center were selected because they treat patients 
who experience a range of symptoms resulting 
from treatment: the Bone Marrow and Stem Cell 
Transplant Clinic, Breast Medical Oncology Clinic 
(chemotherapy), and Radiation Oncology Clinic for 
head and neck, and prostate cancer patients. All 
patients were undergoing active treatment.
Purposive sampling is a qualitative research 
technique involving strategic choices about which 
individuals to include in a sample (typically not 
probability-based).20 A purposive sampling strategy 
was implemented to recruit at least 20 percent 
of cancer patients who were ages 60 years and 
older, were African American, or had a high school 
education or less. Patients could fulfill recruitment 
categories for more than one group by meeting 
multiple criteria. We included age, race, ethnicity, and 
education in the sampling strategy to generalize to 
the academic medical center’s cancer population 
and to other hospital systems. Additionally, prior 
research has shown that these groups may have 
more difficulty understanding, and may respond in 
different ways to, health-related questionnaires.21-23 
Cancer patients who are older, are in a racial or 
ethnic minority, or who have a low education 
level are also at risk of disparities in treatment 
outcomes.24-28 Ethnicity was coded as “Hispanic” 
or “non-Hispanic” based on the demographic 
questionnaire, regardless of race.
Institutional Review Board (IRB) approval was 
obtained from the University of North Carolina at 
Chapel Hill. Patients in each phase were given an 
incentive of $25. Clinicians were not incentivized. 
Different cancer patients were recruited for Phases 1 
and 2.
Selection of Symptoms and Questionnaires
First, our multidisciplinary research team decided 
which symptoms to include in the screener PRO 
measure. The symptoms needed to be applicable 
to patients across a variety of cancer types and 
treatments and the measure needed to be brief. 
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Note: Patient-Reported Symptom Monitoring (PRSM) system
We conducted a literature review,10-11,17,29-32 and the 
research team was unanimous in their decision to 
include the National Cancer Institute (NCI)’s list 
of symptoms to assess in clinical trials (fatigue, 
insomnia, pain, appetite loss, dyspnea, cognitive 
problems, anxiety, nausea, depression, sensory 
neuropathy, constipation, and diarrhea).33 The only 
exception was that constipation was not included 
in the screener. The study team also included 
headache, cough, rash, and urine leakage – given 
their moderate prevalence and effects on quality 
of life.34-35 Quality of life was included as a domain – 
given its relevance for prognosis36 and importance 
to patients. Finally, the research team felt it was 
important to give patients an opportunity to “set 
an agenda” for what they would like to discuss with 
their clinician to better personalize care.
Symptoms were operationalized with 16 items 
adapted from the PRO version of the NCI Common 
Terminology Criteria for Adverse Events (PRO-
CTCAE);37 3 items from the Patient-Reported 
Outcomes Measurement Information System 
(PROMIS) Global Health scale assessing perceived 
health, general quality of life, and the ability to 
conduct daily activities;38 and 2 items written by 
the authors (21 total items: see Appendix A). The 
PRO-CTCAE was selected because it is a PRO 
developed to closely match clinicians’ toxicity 
ratings, and patients and clinicians were involved in 
its development.37 The study team wrote an item to 
assess “other symptoms not listed” for flexibility in 
reporting uncommon symptoms. The PROMIS Global 
Health scale was selected because it has satisfactory 
psychometric properties and national benchmarks 
Figure 1. Overview of Two Research Phases for Development and Usability Testing
DEVELOPMENT 
OF PRSM 
QUESTIONNAIRES 
WITH  
CLINICIANS
PHASE 1
ROUND 1 
COGNITIVE 
INTERVIEWS 
WITH 25 
CANCER 
PATIENTS
ROUND 2 
COGNITIVE 
INTERVIEWS 
WITH 10 
MORE 
CANCER 
PATIENTS
QUESTIONS 
REVISED 
BASED ON 
PATIENT 
FEEDBACK
PROGRAMMING 
PRSM SYSTEM INTO 
NORTH CAROLINA 
CANCER HOSPITAL 
SYSTEM
REAL-TIME TESTING 
WITH 39 CANCER 
PATIENTS
REAL-TIME TESTING 
WITH 12 CLINICIANS
INTERVIEWS 
WITH 20 OUT 
OF 39 CANCER 
PATIENTS 
ABOUT PRSM 
EXPERIENCE
PHASE 2
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for score comparisons,39 and it was developed with 
patient and clinician input.38 No measures were found 
to assess agenda setting, thus the research team 
wrote the following item: “What would you like to 
talk to your nurse or doctor about today?”
A seven-day time frame was selected because the 
interval is short enough for accurate recall yet allows 
for assessment of change.40 This time frame is also 
consistent with national initiatives such as PRO-
CTCAE37and PROMIS.38-39
Study Design
Phase 1: Cognitive Interviews
In Phase 1, we conducted in-depth cognitive 
interviews with cancer patients about the 21-item 
screener questionnaire. This was done to make sure 
the questions were comprehendible and measured 
what they were supposed to measure from the 
patient’s perspective (i.e., face validity), and that 
patients could provide valid responses reflective of 
their symptom and functional status. We conducted 
cognitive interviews in two rounds with a total of 
35 patients. Trained interviewers held bachelor’s 
and master’s degrees and had at least two years of 
experience interviewing patient populations.
Patients in the first round of cognitive testing 
evaluated the 21 screening questions and a mock-
up of a report summarizing responses from a 
fictional patient. Substantially revised questions were 
reviewed with 10 additional patients. Items were 
defined as “substantially revised” if their revision 
involved the following: (1) adding or removing words 
that changed the meaning of a phrase; (2) word 
substitutions that in the judgment of the research 
team were more than a semantic simplification; or 
(3) changes to response options. The determination 
of which items qualified as “substantially revised” 
was a subjective judgment done by consensus. 
Coding for comprehensibility issues was done after 
interviews. We expected few problems to be noted 
for PRO-CTCAE and PROMIS questions because 
they had undergone cognitive testing at other 
academic centers.37-38
Phase 2: Patients’ and Clinicians’ Perceptions of 
Acceptability and the Value of Discussing PRO 
Measures During Clinical Encounters
LimeSurvey was chosen as the Web server-based 
software and was installed on hospital servers. 
LimeSurvey is an open source, online survey 
application written in PHP and distributed under the 
GNU General Public License (LimeSurvey.org).
Cancer patients were provided with an Internet-
enabled tablet computer (XOOM or iPad) in the 
clinic waiting room and were logged into the survey 
by a research assistant. They were asked to complete 
the 21-item screener questionnaire before seeing 
their clinician. A summary of patient responses was 
automatically generated that listed symptoms, in 
order from most to least severe. A research assistant 
gave a hard copy summary to both the patient and 
clinician prior to the visit.
Immediately following the visit with the clinician, 39 
cancer patients completed a questionnaire about 
acceptability, perceived value, and comprehension 
of the screening questions and summary sheet. 
Additionally, 20 of the 39 patients completed a 
semistructured interview after using the web-based 
system to elicit feedback on which aspects were 
useful or not useful and suggestions for revisions. 
These 20 patients were selected by inviting every 
other person in order of assessment date. If a patient 
was unavailable to complete the interview after the 
clinical visit, the next patient was selected.
Clinicians completed a questionnaire after each 
patient visit about the perceived value and utility of 
their patient’s PRO summary. We collected clinician’s 
gender, credentials (e.g., MD, nurse practitioner, etc.), 
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Note: *25 patients participated in round 1 of cognitive interviews and 10 patients in round 2.
and number of years in practice. In order to limit 
the burden, no information was collected about the 
patient’s disease stage. Treatment type was recorded 
based on the clinic the patient was attending (breast 
chemotherapy, radiation clinic for prostate or head 
and neck cancer, or bone marrow transplant clinic).
Results
Phase 1: Cognitive Interviews with Cancer Patients 
about the PRO Measure
Two rounds of cognitive interviews were 
conducted in order to ensure that questions were 
comprehensible to patients. Twenty-five cancer 
patients participated in round 1 and 10 additional 
patients participated in round 2; 66 percent were 
Caucasian, 29 percent had a high school education or 
less, and 49 percent were ages 60 and older (Table 1).
Three symptom terms were revised based on 
patient feedback (Appendix B). Several participants 
had difficulty understanding the phrase “loss of 
control of urine,” and it was changed to “loss of 
urine or leakage.” A qualifier was added for anxiety 
(worrying). “Fatigue, tiredness, or lack of energy was 
amended to “tiredness, lack of energy, or fatigue” 
because “fatigue” was difficult for several patients 
to read. We also revised the phrasing of questions 
measuring symptom severity (13 items) because 
10 out of 25 patients had difficulty comprehending 
what was being assessed (Appendix B). The phrase, 
“In the last seven days, what was the severity of 
your [symptom] at its worst?” was revised to, “In the 
last 7 days, rate your worst [symptom].”In Round 2, 
patients reported that all rewritten questions were 
satisfactory (Appendix A).
Table 1. Demographic Characteristics of Cancer Patients in Phase 1 and Phase 2
CANCER PATIENT  
COGNITIVE INTERVIEWS 
(n=35)* 
n (%)
CANCER PATIENT USABILITY 
TESTING IN CLINIC 
(n=39) 
n (%)
Clinic
Breast 
 (Chemotherapy)
9 (26%) 10 (26%)
Head and Neck 
 (Radiation)
10 (28%) 9 (23%)
Prostate 
 (Radiation)
8 (23%) 10 (26%)
Bone Marrow 
 (Transplant)
8 (23%) 10 (26%)
Age
18–40 1 (3%) 3 (8%)
41–50 4 (11%) 4 (10%)
51–60 13 (37%) 17 (44%)
61+ 17 (49%) 15 (38%)
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Note: *25 patients participated in round 1 of cognitive interviews and 10 patients in round 2.
Table 1. Demographic Characteristics of Cancer Patients in Phase 1 and Phase 2 (Cont’d)
CANCER PATIENT  
COGNITIVE INTERVIEWS 
(n=35)* 
n (%)
CANCER PATIENT USABILITY 
TESTING IN CLINIC 
(n=39) 
n (%)
Gender
Female 17 (49%) 20 (51%)
Ethnicity
Hispanic 1 (3%) 1 (3%)
Race
Caucasian 23 (66%) 21 (54%)
African American 12 (34%) 15 (38%)
Other 0 (0%) 3 (8%)
Education
) High School 10 (29%) 16 (41%)
Some College 10 (29%) 10 (26%)
College 8 (23%) 8 (21%)
Postgraduate 7 (20%) 5 (13%)
Marital Status
Never Married 2 (6%) 3 (8%)
Married/Partner 21 (60%) 26 (66%)
Separated/Divorced 10 (29%) 9 (23%)
Widowed 2 (6%) 1 (3%)
Occupation
Employed 12 (34%) 15 (38%)
Retired 13 (37%) 10 (26%)
Disabled 9 (26%) 10 (26%)
Other 1 (3%) 4 (10%)
Income
)$20,000 8 (23%) 13 (33%)
$20,001–$60,000 10 (28%) 13 (33%)
$60,001+ 15 (43%) 12 (31%)
No response 2 (6%) 1 (3%)
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Phase 2: Usability Testing During Clinical Encounters
Cancer Patients’ Perceptions of Acceptability and 
Value
In usability testing during clinical care, 82 percent 
of 39 additional cancer patients were Caucasian, 
41 percent had a high school education or less, and 
38 percent were ages 60 years and older (Table 1). 
Gender was balanced across the clinics.
Most cancer patients felt that reviewing a summary 
of their PRO measure with their clinician was helpful 
in discussing health issues (92 percent), wanted to 
review their PRO results with their clinician during 
future visits (82 percent), and would recommend it 
to other patients (87 percent). Over half of patients 
(64 percent) reported that the screening questions 
were helpful in discussing medical issues with their 
provider that might have been missed otherwise.
The majority (80 percent) chose to set an agenda 
for what they would like to discuss with their clinician 
during the visit. For instance, in Figure 2, an over 
40-year-old African American woman receiving 
chemotherapy for breast cancer wanted to talk to 
her doctor about how long her numbness would 
last. She reported her numbness as being “mild,” but 
the agenda setting item permitted the patient to 
indicate it was important to discuss during the visit.
Figure 2. PRO Measure Summary from a Patient
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When asked about the length of the web-based 
PRO measure, 92 percent of cancer patients were 
willing to answer additional questions; of those, 28 
percent were willing to complete 10 more questions, 
15 percent to complete 20 more questions, and 15 
percent to complete 30 or more questions. Over half 
(67 percent) were willing to complete the survey 
at home on a computer or smartphone and had 
Internet access, 15 percent were willing to complete 
the screening questions at home but did not have 
Internet access, and 8 percent did not want to 
complete the screening items at home (5 percent 
responded “I don’t know” and 5 percent did not 
provide an answer). See Table 2 for additional results 
with cancer patients. In Table 2, the response option 
“somewhat easy” was given its own column because 
it may have been a more socially acceptable way to 
indicate less enthusiasm than “difficult.”
We also conducted one-on-one interviews with 20 
out of 39 patients immediately after their clinical visit 
to solicit feedback. Cancer patients reported high 
satisfaction with the web-based screening tool and 
PRO summary, and had few recommendations for 
revisions. Positive comments included finding the 
tablet computer easier and faster to use than paper-
and-pencil questionnaires. Negative comments 
included needing a slightly longer time to use the 
on-screen keyboard to respond to open-ended 
questions (<10 percent).
Clinicians’ Perceptions of Acceptability and Utility
Twelve clinicians were predominantly MDs (67 
percent), male (58 percent), and had been practicing 
for an average of 10 years. Three clinicians treated 
breast cancer: two MDs (one male, one female) and 
Table 2. Cancer Patient Impressions of Acceptability and Perceived Value (n=39)
VERY  
EASY/  
EASY
SOMEWHAT 
EASY
NEITHER  
DIFFICULT  
NOR EASY
VERY  
DIFFICULT/  
DIFFICULT/ 
SOMEWHAT  
DIFFICULT
NO  
ANSWER
NO  
SYMPTOMS 
IN LAST 7 
DAYS 
Seeing 
questions on 
computer
36 
(92.2%)
1 
(2.6%)
0
2 
(5.2%)
0 0
Using tablet 
computer 
to answer 
questions
34 
(87.1%)
3
(7.7%)
1
(2.6%)
1 
(2.6%)
0 0
Answering 
questions about 
your symptoms 
and health
37 
(94.8%)
0 0
2 
(5.2%)
0 0
Understanding 
paper copy of 
your answers
31 
(79.5%)
0
2 
(5.1%)
0 0
6 
(15.4%)
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Note: PRSM = Patient-Reported Symptom Monitoring (PRSM) System
Table 2. Cancer Patient Impressions of Acceptability and Perceived Value (n=39) (Cont’d)
VERY  
SATISFIED/ 
SATISFIED
SOMEWHAT 
SATISFIED
NEITHER  
SATISFIED 
NOR  
UNSATISFIED
VERY  
DISSATISFIED/ 
DISSATISFIED/ 
SOMEWHAT 
DISSATISFIED
NO  
ANSWER
NO  
SYMPTOMS 
IN LAST 7 
DAYS
In general, how 
satisfied were 
you with using 
the computer 
to report your 
symptoms?
37 
(94.8%)
0
1 
(2.6%)
0
1 
(2.6%)
0
Overall, how 
satisfied are you 
with using the 
PRSM system?
32 
(82.1%)
2 
(5.1%)
0 0
5 
(12.8%)
0
VERY  
HELPFUL/  
HELPFUL
SOMEWHAT 
HELPFUL
NEITHER 
HELPFUL 
NOR  
UNHELPFUL
VERY  
UNHELPFUL/ 
UNHELPFUL/ 
SOMEWHAT 
UNHELPFUL
NO  
ANSWER
NO  
SYMPTOMS 
IN LAST 7 
DAYS
How helpful was 
the symptom 
survey to 
remind you of 
symptoms you 
experienced in 
the last 7 days?
25 
(64.1%)
2 
(5.1%)
2 
(5.1%)
0
4 
(10.3%)
6 
(15.4%) 
How helpful was 
the symptom 
survey for 
talking to 
your doctor/
nurse about 
symptoms you 
experienced?
30 
(76.9%)
6 
(15.4%)
2 
(5.1%)
0 0
1 
(2.6%) 
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one female Nurse Practitioner (NP). Two clinicians 
treated head and neck cancer: one male MD and one 
female NP. Four clinicians treated prostate cancer: 
three MDs (all male) and one female NP. Three 
clinicians treated bone marrow transplant patients: 
two MDs (both male) and one female NP.
The average number of patients seen by each 
clinician for this study was 2.6 (SD=1.9). In general, 
clinicians who saw multiple study patients reported 
similar satisfaction scores across patients, and thus 
we averaged across each clinician. In other words, 
each clinician contributed one averaged score in 
Table 3. As a sensitivity analysis, Table 3 presents 
results separately for seven clinicians unaffiliated 
with our study team and five clinicians who were 
part of our study team. Scores were similar whether 
from clinicians who were affiliated or unaffiliated 
with our study team, and thus we report in the text 
on the total (12 clinicians). In Table 3, the response 
option “somewhat helpful” was given its own column 
because it may have been a more socially acceptable 
way to indicate less enthusiasm than “unhelpful.”
Out of 39 total patients seen, there were 7 instances 
where the clinician did not receive the symptom 
summary before the patient visit (3 breast patients, 
2 head and neck, and 2 bone marrow transplant 
patients), and thus they did not complete an 
acceptability questionnaire. In one case the printer 
was not working, and in the other 6 cases the patient 
did not complete the questionnaire before the 
clinician was ready to see them. These 7 instances 
are not included in Table 3.
Most clinicians found the PRO summary to be easy 
to interpret (83 percent), helpful for communicating 
with patients (67 percent), and would recommend 
it to future patients (92 percent) (Table 3). The PRO 
summary was perceived by clinicians to be most 
useful for documenting the Review of Symptoms (92 
percent). Five clinicians adjusted the treatment plan 
and, of these, four (80 percent) felt that the PRO 
summary was “very helpful” or “helpful” in changing 
the treatment plan (the fifth rated it as “neither 
helpful nor unhelpful”).
Importantly, most clinicians (92 percent) reported 
that discussing the PRO summary with their patient 
during the clinical visit did not change the amount 
of consultation time (one reported a five-minute 
decrease and one reported a five-minute increase). 
Clinicians reported that 83 percent of patients talked 
with them about symptoms reported on the PRO 
measure (13 percent did not experience symptoms 
in the last seven days, and thus symptoms were not 
relevant to discuss). This left 4 percent (n=2) patient-
clinicians dyads who received a hard copy of the 
PRO summary but did not directly discuss it during 
the visit.
The seven clinicians unaffiliated with our study team 
provided several comments: (1) “This would be great 
for full review of symptoms; add questionnaires 
such as IPSS [International Prostate Symptom 
Score Questionnaire], and medication/allergies”; (2) 
“May take time to familiarize with better”; (3) “I like 
that patient lists their questions for visit” [agenda 
setting]; and (4) “My patient put the important 
symptom in ‘other’ [field] and wrote ‘nothing’ in 
agenda field. I didn’t notice ‘other’ [field] until after 
she left, but we had talked about it anyway.”
Comments from the five clinicians who were part of 
our study team had similar themes: (1) “patient really 
liked survey”; (2) “needs to be ready and in the door 
for my review prior to seeing pt.”; and (3) “providers 
should get primer on the process before starting.”
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Table 3. Clinician Impressions of PRO Summary (n=12)
ITEM
AFFILIATED OR 
UNAFFILIATED  
CLINICIANS
VERY  
HELPFUL/ 
HELPFUL
SOMEWHAT 
HELPFUL
NEITHER  
HELPFUL 
NOR  
UNHELPFUL
VERY  
UNHELPFUL/  
UNHELPFUL/  
SOMEWHAT  
UNHELPFUL
Overall, how helpful 
was summary of 
patient’s answers to 
prepare for visit?
Seven 
Unaffiliated 
Clinicians
5 
(71.4%)
1 
(14.3%)
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
3 
(60.0%)
2 
(40.0%)
0 0
How helpful or 
unhelpful: 
General health 
question
Seven 
Unaffiliated 
Clinicians
4 
(57.1%)
1 
(14.3%)
1 
(14.3%)
1 
(14.3%)
Five Clinicians 
Affiliated with 
Our Study Team
4 
(80.0%)
1 
(20.0%)
0 0
How helpful or 
unhelpful: 
General quality of 
life question
Seven 
Unaffiliated 
Clinicians
6 
(85.7%)
0
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
4 
(80.0%)
1 
(20.0%)
0 0
How helpful or 
unhelpful: 
Carry out daily 
activities question
Seven 
Unaffiliated 
Clinicians
4 
(57.1%)
2 
(28.6%)
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
3 
(60.0%)
2 
(40.0%)
0 0
How helpful or 
unhelpful: 
Symptom questions
Seven 
Unaffiliated 
Clinicians
6 
(85.7%)
0
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
4 
(80.0%)
1 
(20.0%)
0 0
How helpful or 
unhelpful: 
Agenda setting 
(Issues that patient 
listed to talk about 
during appointment)
Seven 
Unaffiliated 
Clinicians
5 
(71.4%)
0
2 
(28.6%)
0
Five Clinicians 
Affiliated with 
Our Study Team
3 
(60.0%)
2 
(40.0%)
0 0
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Note: PRSM = Patient-Reported Symptom Monitoring (PRSM) System
Table 3. Clinician Impressions of PRO Summary (n=12) (Cont’d)
ITEM
AFFILIATED OR 
UNAFFILIATED 
CLINICIANS
VERY 
HELPFUL/ 
HELPFUL
SOMEWHAT 
HELPFUL
NEITHER 
HELPFUL 
NOR  
UNHELPFUL
VERY  
UNHELPFUL/ 
UNHELPFUL/ 
SOMEWHAT 
UNHELPFUL
How helpful was 
PRSM for talking 
to your patients 
about symptoms 
and health 
conditions 
they were 
experiencing?
Seven 
Unaffiliated 
Clinicians
3 
(42.9%)
3 
(42.9%)
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
3 
(60.0%)
2 
(40.0%)
0 0
How helpful 
was PRSM for 
documenting 
patient’s review 
of systems?
Seven 
Unaffiliated 
Clinicians
6 
(85.7%)
0
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
5 
(100.0%)
0 0 0
ITEM
AFFILIATED OR 
UNAFFILIATED 
CLINICIANS
VERY 
EASY/ 
EASY
SOMEWHAT 
EASY
NEITHER  
DIFFICULT 
NOR EASY
VERY  
DIFFICULT/  
DIFFICULT/ 
SOMEWHAT 
DIFFICULT
Easy or difficult 
to understand 
paper copy 
of patient’s 
answers?
Seven 
Unaffiliated 
Clinicians
6 
(85.7%)
0 0
1 
(14.3%)
Five Clinicians 
Affiliated with 
Our Study Team
4 
(80.0%)
1 
(20.0%)
0 0
ITEM
AFFILIATED OR 
UNAFFILIATED 
CLINICIANS
VERY  
SATISFIED/ 
SATISFIED
SOMEWHAT 
SATISFIED
NEITHER 
SATISFIED 
NOR  
UNSATISFIED
VERY  
DISSATISFIED/ 
DISSATISFIED/ 
SOMEWHAT 
DISSATISFIED
Satisfaction  
with PRSM 
System
Seven 
Unaffiliated 
Clinicians
5 
(71.4%)
1 
(14.3%)
1 
(14.3%)
0
Five Clinicians 
Affiliated with 
Our Study Team
3 
(60.0%)
2 
(40.0%)
0 0
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Discussion
We conducted a two-phase qualitative study to 
develop a web-based PRO system to collect, store, 
and summarize cancer patients’ self-reported 
symptoms and functional status for use during 
routine cancer care. Our process involved patient 
and clinician feedback and testing during clinical 
encounters. This is the first study, to our knowledge, 
that assesses clinicians’ and patients’ perceptions 
in real time about the acceptability and utility of 
discussing PRO measures during routine care. 
Both cancer patients and clinicians reported that 
discussing a PRO measure during an outpatient visit 
was useful, acceptable, and feasible.
Cancer patients reported that it was easy to 
complete 21 items on a tablet computer in the 
waiting room. The majority felt that discussing 
a PRO measure with their clinician during an 
outpatient visit was helpful in reviewing health issues 
and would recommend it to other patients. Most 
patients also chose to set an “agenda” for topics 
they would like to discuss with their clinician during 
the visit. Discussing PRO measures with patients 
may promote patients’ involvement in their own care 
by communicating their health experiences in real 
time, and thus may improve care.11,32
Clinicians reported that reviewing a PRO summary 
with patients did not lengthen consultation time 
and was most useful for documenting the Review 
of Symptoms, indicating that PRO measures may 
help clinicians focus attention on their patients’ 
most problematic symptoms. Future testing will be 
necessary to determine when the PRO screener is 
sufficient for identifying problematic symptoms and 
when additional modules are necessary that are 
specific to types of cancer or treatments.
We observed slightly lower satisfaction among 
clinicians with the PRO system than among patients. 
Lower clinician satisfaction may have been due to 
the following reasons: (1) being unfamiliar with how 
to interpret PRO measures; (2) multiple suggestions 
for adding disease- and treatment-specific 
symptoms and better functionality of the system; 
or (3) for four clinicians who reported that the PRO 
summary was “somewhat helpful” or “neither helpful 
nor unhelpful,” they may have had less interest in the 
project prior to their involvement than had those 
who indicated it was more useful. We believe these 
suggestions for improvement indicate moderate 
to strong interest among approximately two-thirds 
of the clinicians in our study in continuing to use 
and improve PRO measures during clinical care. 
Future research should consider examining trends of 
perceived acceptability and usefulness as clinicians 
become more familiar with PRO systems over time. 
The Diffusion of Innovation Theory41 may be useful 
for this purpose. Given our small sample size and 
cross-sectional data collection, we were not able to 
determine if clinicians reported greater satisfaction 
over multiple uses.
Enhancing functionality of web-based PRO systems 
to optimally meet clinicians’ needs is a systematic 
barrier occurring across health systems. Less than 
half of web-based PRO systems in cancer care 
that were identified in a recent systematic review 
are linked to electronic health records (EHRs), and 
only 15 percent are linked to billing procedures.18 
Therefore, the field would benefit from guidelines 
for incorporating PRO questionnaires into clinical 
workflow and decision-making, EHRs, and 
administrative systems.
PRO systems integrated into routine cancer care 
may also serve as a foundation for a “learning health 
care system” where symptoms, treatments, and 
outcomes from all cancer patients are utilized in 
improving care rather than from just the few cancer 
patients who enter a clinical trial.42-43 A state-of-the-
art learning health care system would continually 
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assemble clinical data from multiple sources (e.g., 
all patients attending clinics, registries, EHRs, 
and clinical trials) to provide the most up-to-date 
evidence for clinicians and researchers.42-43
Feasibility and Sustainability
Feasibility and sustainability issues will need to be 
addressed in future iterations. For the purposes of 
this study, the research assistant logged the patient 
into the tablet computer with a study ID number, 
printed out a hard copy of the PRO summary, and 
then gave copies to the clinician and patient. In 
future iterations, a front desk staff person may be 
able to enter the patient’s medical record number 
and help with “how-to” questions such as how to 
access the on-screen keyboard. Stukenborg et 
al.44 also found that palliative care cancer patients 
requested assistance with a tablet computer. Future 
research should keep this in mind when designing 
interfaces and plans to pretest PRO systems with 
diverse patients.
If patients are given the option to complete PRO 
measures on a home computer or smartphone prior 
to the visit, additional programming features and 
clinical procedures will be needed. For instance, 
programming flags will need to be in place to ensure 
that the questions have been completed prior 
to seeing the clinician and have valid responses, 
and that missing data is minimized.44 Additionally, 
procedures for alerting clinicians to immediate 
issues and for following up with the patient prior to 
appointments will need to be in place.
This approach requires that patients have access to 
online patient portals or interactive voice response 
systems to complete PRO measures prior to visits. 
Concerns have been raised that web-based PRO 
systems may not be feasible for underserved 
populations.46 However, the Pew Internet and 
American Life annual surveys indicate that 74 
percent of adults go online and Internet use among 
adults ages 60 years and older – and those with a 
high school education or less – has been rising.47 
Mobile technology, in particular, is increasing among 
underserved populations.47 Over 60 percent of 
the diverse cancer patients in our study reported 
having access to the Internet and would be willing 
to complete PRO measures at home prior to 
appointments.
Moving forward, as PRO systems become 
increasingly complex, training clinicians on using 
and interpreting PRO measures will be critical for 
future success. For instance, the PROMIS global 
health measures can be scored by transforming 
raw scores into T-scores (mean of 50 and standard 
deviation of 10).39 T-scores may not be intuitive, and 
training is advised so that clinicians can help patients 
understand their scores.
Limitations
This study was limited to one large, comprehensive 
cancer center with small samples of patients and 
clinicians, although the academic medical center 
treats patients who are diverse in terms of age, 
education level, and race (African American). We 
used purposive sampling within each of these 
demographic groups to maximize diversity, but 
further research is needed to determine if results 
generalize to other academic centers, community 
hospitals, and patients of other races or Hispanic 
ethnicity.
Future testing should also expand purposive 
sampling to include a greater variety of disease 
stages and treatment types (e.g., mastectomy, nerve-
sparing robotic-assisted prostatectomy, hormone 
therapy). Symptoms are likely to vary across 
disease stages and treatment groups, and it will be 
important to determine whether the PRO screening 
questions have adequate symptom coverage for 
different groups.
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Future testing is also needed to evaluate the 
psychometric properties of questions adapted 
from the PRO-CTCAE based on patient feedback. 
Testing at other medical centers and community 
practices is warranted to determine the validity and 
reliability of these PRO items to serve as screeners 
for problematic symptoms during cancer care. In 
addition, feasibility testing is encouraged to minimize 
disruptions to the clinic workflow.
Our study had several strengths, including 
methodological rigor for qualitative research and 
PRO evaluation. In Phase I, our multidisciplinary 
team chose the most informative PRO items for 
a brief screener, then conducted cognitive testing 
with cancer patients who were diverse in terms of 
clinical and demographic characteristics. In Phase 
II, we assessed both cancer patients’ and clinicians’ 
perceptions during real-time clinical encounters.
Conclusion
Both cancer patients and clinicians reported during 
real-time testing that discussing a PRO measure 
during an outpatient visit was useful, acceptable, and 
feasible. Real-time symptom reports involve cancer 
patients in their own care by communicating their 
health experiences and providing the opportunity to 
convey what is most important to them to discuss 
during their visits. Providing health care practitioners 
with real-time, patient-specific summaries of 
symptoms may allow clinicians to respond to 
concerns rapidly and effectively. The current study 
contributes to best practices for integrating real-
time, patient-reported symptom and functional 
status data into routine cancer care.
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Appendix A. Questions Reviewed During Cognitive Interviews and Final Screener Items
DOMAIN
21 ITEMS THAT  
UNDERWENT COGNITIVE  
INTERVIEWING
FINAL VERSION OF THE  
21-ITEM SCREENER  
APPLICABLE ACROSS ALL  
CANCER AND TREATMENT TYPES
Agenda Setting 
for Visit
“What would you like to talk to nurse or 
doctor about today?”3
What would you like to talk to 
nurse or doctor about today?
Insomnia What was the SEVERITY of your 
INSOMNIA (INCLUDING DIFFICULTY 
FALLING ASLEEP, STAYING ASLEEP, 
OR WAKING UP EARLY) at its WORST?1
Rate your worst insomnia 
(trouble sleeping).
Decreased 
Appetite
What was the SEVERITY of your 
DECREASED APPETITE?1
Rate your worst decreased 
appetite.
Nausea What was the SEVERITY of your 
NAUSEA at its WORST?1
Rate your worst upset stomach.
Pain Frequency How OFTEN did you have PAIN?1 How often did you have pain?
Pain Intensity What was the SEVERITY of your PAIN 
at its WORST?1
Rate your worst pain.
Depression What was the SEVERITY of your 
SAD or UNHAPPY FEELINGS at their 
WORST?1
Rate your worst sad or unhappy 
feelings.
Fatigue What was the SEVERITY of your 
FATIGUE, TIREDNESS, OR LACK OF 
ENERGY at its WORST?1
Rate your worst tiredness, lack of 
energy, fatigue.
Headache What was the SEVERITY of your 
HEADACHE at its WORST?1
Rate your worst headache.
Anxiety What was the SEVERITY of your 
ANXIETY at its WORST?1
Rate your worst anxiety 
(worrying).
Neuropathy What was the SEVERITY of your 
NUMBNESS OR TINGLING IN YOUR 
HANDS OR FEET at its WORST?1
Rate your worst numbness or 
tingling in your hands or feet.
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Appendix A. Questions Reviewed During Cognitive Interviews and Final Screener Items 
(Cont’d)
DOMAIN
21 ITEMS THAT  
UNDERWENT COGNITIVE  
INTERVIEWING
FINAL VERSION OF THE  
21-ITEM SCREENER  
APPLICABLE ACROSS ALL  
CANCER AND TREATMENT TYPES
Dyspnea What was the SEVERITY of your 
SHORTNESS OF BREATH?1
Rate your worst shortness of 
breath.
Cough What was the SEVERITY of your 
COUGH at its WORST?1
Rate your worst cough.
Trouble 
Concentrating
What was the SEVERITY of your 
PROBLEMS WITH CONCENTRATION at 
their WORST?1
Rate your worst problems with 
concentration.
Diarrhea How OFTEN did you have LOOSE OR 
WATERY STOOLS (DIARRHEA)?1
How often did you have loose or 
watery stools (diarrhea).
Loss of control 
of urine
How OFTEN did you have LOSS OF 
CONTROL OF URINE (LEAKAGE)? 1
How often did you have loss of 
control of urine (leakage).
Rash Did you have any RASH?1 Did you have a rash? (yes/no)
Other 
Symptoms  
Not Listed
Did you have any other symptoms not 
listed?3
Did you have any other 
symptoms not listed?
Overall Health In general, would you say your  
HEALTH is:2  
Excellent, Very Good, Good, Fair, Poor? 
In general, would you say your 
health is:  
Excellent, Very Good, Good, Fair, 
Poor?
Quality of Life In general, would you say your 
QUALITY OF LIFE is:2  
Excellent, Very Good, Good, Fair, Poor?
In general, would you say your 
quality of life is: 
Excellent, Very Good, Good, Fair, 
Poor?
Daily Activities To what extent are you able to carry out 
your everyday physical activities such 
as walking, climbing stairs, carrying 
groceries, or moving a chair?2
To what extent are you able to 
carry out your everyday physical 
activities such as walking, 
climbing stairs, carrying groceries, 
or moving a chair?
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Appendix B. Cognitive Interview Results
DOMAIN
ORIGINAL 
WORDING OF 
QUESTION
NUMBER 
REPORTING 
DIFFICULTY 
ANSWERING 
QUESTION
COMMENTS 
FROM ROUND 1 
PARTICIPANTS 
(n=25)
REVISED 
WORDING  
OF QUESTION
COMMENTS 
FROM ROUND 2 
PARTICIPANTS 
(n=10  
ADDITIONAL 
PATIENTS)
Severity 
Stem
What was 
the severity 
of (your) 
[symptom] 
at its worst?
10/25 “Do you want 
to know how 
bad it is or 
how often it 
occurred?”
“Difficult to 
compute ‘at its 
worst.’ It often 
starts one 
way and ends 
another. Do 
you mean on a 
specific day?”
“Tough when 
you have a 
lot of one 
symptom, but 
it isn’t that 
bad.” “Also 
difficult when 
you don’t have 
a symptom to 
report.”
“At its worst – 
as compared 
to what?”
“I didn’t read 
far enough 
to get to the 
‘at its worst’ 
part so I didn’t 
factor that into 
my answers.”
Rate your 
worst 
[symptom].
Acceptable as 
rewritten
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Appendix B. Cognitive Interview Results (Cont’d)
DOMAIN
ORIGINAL 
WORDING OF 
QUESTION
NUMBER 
REPORTING 
DIFFICULTY 
ANSWERING 
QUESTION
COMMENTS 
FROM ROUND 1 
PARTICIPANTS 
(n=25)
REVISED 
WORDING  
OF QUESTION
COMMENTS 
FROM ROUND 2 
PARTICIPANTS 
(n=10  
ADDITIONAL 
PATIENTS)
Fatigue Fatigue, 
tiredness, 
or lack of 
energy
3/25 Difficulty 
reading or 
understanding 
the word 
“fatigue.”
Tiredness, 
lack of 
energy, or 
fatigue
Acceptable as 
rewritten
Anxiety Anxiety 2/25 Difficulty 
reading word 
“anxiety” 
or trouble 
understanding 
concept
Anxiety 
(worrying)
Acceptable as 
rewritten
Bladder 
Control
Loss of 
control 
of urine 
(leakage)
4/25 Difficulty 
understanding 
what control of 
urine meant
Leak urine/
urine 
leakage
Acceptable as 
rewritten
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